-
1
-
-
78650874372
-
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
-
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 471-478
-
-
Abrams, T.J.1
Lee, L.B.2
Murray, L.J.3
Pryer, N.K.4
Cherrington, J.M.5
-
2
-
-
37249072373
-
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
-
DOI 10.1007/s00280-007-0498-4
-
Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D (2008) A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 61: 515-524 (Pubitemid 350275988)
-
(2008)
Cancer Chemotherapy and Pharmacology
, vol.61
, Issue.3
, pp. 515-524
-
-
Britten, C.D.1
Kabbinavar, F.2
Randolph Hecht, J.3
Bello, C.L.4
Li, J.5
Baum, C.6
Slamon, D.7
-
3
-
-
42949148257
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
-
Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810-1816
-
(2008)
J Clin Oncol
, vol.26
, pp. 1810-1816
-
-
Burstein, H.J.1
Elias, A.D.2
Rugo, H.S.3
Cobleigh, M.A.4
Wolff, A.C.5
Eisenberg, P.D.6
Lehman, M.7
Adams, B.J.8
Bello, C.L.9
Deprimo, S.E.10
Baum, C.M.11
Miller, K.D.12
-
4
-
-
77957244953
-
-
Camptosar
-
Camptosar (2008) http://media.pfizer.com/files/products/uspi-camptosar. pdf
-
(2008)
-
-
-
5
-
-
54049120234
-
Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: To test or not to test, that is the question
-
Deeken JF, Slack R, Marshall JL (2008) Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer 113: 1502-1510
-
(2008)
Cancer
, vol.113
, pp. 1502-1510
-
-
Deeken, J.F.1
Slack, R.2
Marshall, J.L.3
-
6
-
-
33749505836
-
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
-
DOI 10.1016/S0140-6736(06)69446-4, PII S0140673606694464
-
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338 (Pubitemid 44528723)
-
(2006)
Lancet
, vol.368
, Issue.9544
, pp. 1329-1338
-
-
Demetri, G.D.1
Van Oosterom, A.T.2
Garrett, C.R.3
Blackstein, M.E.4
Shah, M.H.5
Verweij, J.6
McArthur, G.7
Judson, I.R.8
Heinrich, M.C.9
Morgan, J.A.10
Desai, J.11
Fletcher, C.D.12
George, S.13
Bello, C.L.14
Huang, X.15
Baum, C.M.16
Casali, P.G.17
-
7
-
-
33644847440
-
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
-
DOI 10.1200/JCO.2005.02.2194
-
Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35 (Pubitemid 46630490)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.1
, pp. 25-35
-
-
Faivre, S.1
Delbaldo, C.2
Vera, K.3
Robert, C.4
Lozahic, S.5
Lassau, N.6
Bello, C.7
Deprimo, S.8
Brega, N.9
Massimini, G.10
Armand, J.-P.11
Scigalla, P.12
Raymond, E.13
-
8
-
-
67651165187
-
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study
-
Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10: 794-800
-
(2009)
Lancet Oncol
, vol.10
, pp. 794-800
-
-
Faivre, S.1
Raymond, E.2
Boucher, E.3
Douillard, J.4
Lim, H.Y.5
Kim, J.S.6
Zappa, M.7
Lanzalone, S.8
Lin, X.9
Deprimo, S.10
Harmon, C.11
Ruiz-Garcia, A.12
Lechuga, M.J.13
Cheng, A.L.14
-
10
-
-
0032945307
-
Irinotecan therapy in adults with recurrent or progressive malignant glioma
-
Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516-1525 (Pubitemid 29220860)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.5
, pp. 1516-1525
-
-
Friedman, H.S.1
Petros, W.P.2
Friedman, A.H.3
Schaaf, L.J.4
Kerby, T.5
Lawyer, J.6
Parry, M.7
Houghton, P.J.8
Lovell, S.9
Rasheed, K.10
Cloughsey, T.11
Stewart, E.S.12
Colvin, O.M.13
Provenzale, J.M.14
McLendon, R.E.15
Bigner, D.D.16
Cokgor, I.17
Haglund, M.18
Rich, J.19
Ashley, D.20
Malczyn, J.21
Elfring, G.L.22
Miller, L.L.23
more..
-
11
-
-
0037364658
-
Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer
-
DOI 10.1200/JCO.2003.08.058
-
Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21: 807-814 (Pubitemid 46606439)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.5
, pp. 807-814
-
-
Fuchs, C.S.1
Moore, M.R.2
Harker, G.3
Villa, L.4
Rinaldi, D.5
Hecht, J.R.6
-
12
-
-
0026531753
-
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
-
Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20
-
(1992)
J Clin Oncol
, vol.10
, pp. 16-20
-
-
Fukuoka, M.1
Niitani, H.2
Suzuki, A.3
Motomiya, M.4
Hasegawa, K.5
Nishiwaki, Y.6
Kuriyama, T.7
Ariyoshi, Y.8
Negoro, S.9
Masuda, N.10
-
13
-
-
50149083259
-
Pharmacogenetics in colorectal cancer: A systematic review
-
Funke S, Brenner H, Chang-Claude J (2008) Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 9: 1079-1099
-
(2008)
Pharmacogenomics
, vol.9
, pp. 1079-1099
-
-
Funke, S.1
Brenner, H.2
Chang-Claude, J.3
-
14
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, ODwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson III AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
Odwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
Schwartz, M.A.7
Benson Iii, A.B.8
-
15
-
-
33947423448
-
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
-
DOI 10.1158/1078-0432.CCR-06-2328
-
Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13: 1367-1373 (Pubitemid 46450424)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.5
, pp. 1367-1373
-
-
Goodman, V.L.1
Rock, E.P.2
Dagher, R.3
Ramchandani, R.P.4
Abraham, S.5
Gobburu, J.V.S.6
Booth, B.P.7
Verbois, S.L.8
Morse, D.E.9
Liang, C.Y.10
Chidambaram, N.11
Jiang, J.X.12
Tang, S.13
Mahjoob, K.14
Justice, R.15
Pazdur, R.16
-
16
-
-
36849018991
-
Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer
-
Gravalos C, Cassinello J, Fernandez-Ranada I, Holgado E (2007) Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer 6: 691-699 (Pubitemid 350221366)
-
(2007)
Clinical Colorectal Cancer
, vol.6
, Issue.10
, pp. 691-699
-
-
Gravalos, C.1
Cassinello, J.2
Fernandez-Ranada, I.3
Holgado, E.4
-
17
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
18
-
-
20644432867
-
Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
-
DOI 10.1200/JCO.2005.10.017
-
Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 20: 3502-3508 (Pubitemid 46243494)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.15
, pp. 3502-3508
-
-
Hurwitz, H.I.1
Fehrenbacher, L.2
Hainsworth, J.D.3
Heim, W.4
Berlin, J.5
Holmgren, E.6
Hambleton, J.7
Novotny, W.F.8
Kabbinavar, F.9
-
19
-
-
55049136730
-
Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies
-
Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13: 1084-1096
-
(2008)
Oncologist
, vol.13
, pp. 1084-1096
-
-
Hutson, T.E.1
Figlin, R.A.2
Kuhn, J.G.3
Motzer, R.J.4
-
20
-
-
33749544080
-
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
-
DOI 10.1210/jc.2005-2845
-
Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91: 4070-4076 (Pubitemid 44536887)
-
(2006)
Journal of Clinical Endocrinology and Metabolism
, vol.91
, Issue.10
, pp. 4070-4076
-
-
Dong, W.K.1
Young, S.J.2
Hye, S.J.3
Hyo, K.C.4
Jung, H.S.5
Ki, C.P.6
Su, H.P.7
Jung, H.H.8
So, Y.R.9
Gi, R.K.10
Lee, S.-J.11
Jo, K.-W.12
Shong, M.13
-
21
-
-
49149114782
-
Activity of sunitinib in patients with advanced neuroendocrine tumors
-
Kulke M, Lenz HJ, Meropol N, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li J, Baum C, Fuchs C (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26: 3403-3410
-
(2008)
J Clin Oncol
, vol.26
, pp. 3403-3410
-
-
Kulke, M.1
Lenz, H.J.2
Meropol, N.3
Posey, J.4
Ryan, D.P.5
Picus, J.6
Bergsland, E.7
Stuart, K.8
Tye, L.9
Huang, X.10
Li, J.11
Baum, C.12
Fuchs, C.13
-
22
-
-
57349138859
-
Hypertension and proteinuria: A class-effect of antiangiogenic therapies
-
Launay-Vacher V, Deray G (2009) Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 20: 81-82
-
(2009)
Anticancer Drugs
, vol.20
, pp. 81
-
-
Launay-Vacher, V.1
Deray, G.2
-
23
-
-
34247849335
-
Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer
-
DOI 10.1634/theoncologist.12-4-443
-
Los M, Roodhart JM, Voest EE (2007) Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450 (Pubitemid 46698722)
-
(2007)
Oncologist
, vol.12
, Issue.4
, pp. 443-450
-
-
Los, M.1
Roodhart, J.M.L.2
Voest, E.E.3
-
24
-
-
0026680292
-
CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
-
Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-1229
-
(1992)
J Clin Oncol
, vol.10
, pp. 1225-1229
-
-
Masuda, N.1
Fukuoka, M.2
Kusunoki, Y.3
Matsui, K.4
Takifuji, N.5
Kudoh, S.6
Negoro, S.7
Nishioka, M.8
Nakagawa, K.9
Takada, M.10
-
25
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337 (Pubitemid 36109749)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.1 I
, pp. 327-337
-
-
Mendel, D.B.1
Douglas Laird, A.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
Schreck, R.E.7
Abrams, T.J.8
Ngai, T.J.9
Lee, L.B.10
Murray, L.J.11
Carver, J.12
Chan, E.13
Moss, K.G.14
Haznedar, J.O.15
Sukbuntherng, J.16
Blake, R.A.17
Sun, L.18
Tang, C.19
Miller, T.20
Shirazian, S.21
McMahon, G.22
Cherrington, J.M.23
more..
-
26
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
DOI 10.1056/NEJMoa065044
-
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124 (Pubitemid 46089672)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, D.4
Bukowski, R.M.5
Rixe, O.6
Oudard, S.7
Negrier, S.8
Szczylik, C.9
Kim, S.T.10
Chen, I.11
Bycott, P.W.12
Baum, C.M.13
Figlin, R.A.14
-
27
-
-
9144274970
-
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
-
DOI 10.1023/B:CLIN.0000006873.65590.68
-
Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, OFarrell AM, Cherrington JM, Pryer NK (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20: 757-766 (Pubitemid 38019277)
-
(2003)
Clinical and Experimental Metastasis
, vol.20
, Issue.8
, pp. 757-766
-
-
Murray, L.J.1
Abrams, T.J.2
Long, K.R.3
Ngai, T.J.4
Olson, L.M.5
Hong, W.6
Keast, P.K.7
Brassard, J.A.8
O'Farrell, A.M.9
Cherrington, J.M.10
Pryer, N.K.11
-
28
-
-
0038204144
-
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
DOI 10.1182/blood-2002-07-2307
-
OFarrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605 (Pubitemid 36857948)
-
(2003)
Blood
, vol.101
, Issue.9
, pp. 3597-3605
-
-
O'Farrell, A.-M.1
Abrams, T.J.2
Yuen, H.A.3
Ngai, T.J.4
Louie, S.G.5
Yee, K.W.H.6
Wong, L.M.7
Hong, W.8
Lee, L.B.9
Town, A.10
Smolich, B.D.11
Manning, W.C.12
Murray, L.J.13
Heinrich, M.C.14
Cherrington, J.M.15
-
29
-
-
21344457969
-
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
-
DOI 10.1093/annonc/mdi227
-
Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16: 1123-1132 (Pubitemid 41418315)
-
(2005)
Annals of Oncology
, vol.16
, Issue.7
, pp. 1123-1132
-
-
Rea, D.W.1
Nortier, J.W.R.2
Ten Bokkel Huinink, W.W.3
Falk, S.4
Richel, D.J.5
Maughan, T.6
Groenewegen, G.7
Smit, J.M.8
Steven, N.9
Bakker, J.M.10
Semiond, D.11
Kerr, D.J.12
Punt, C.J.A.13
-
30
-
-
53849098896
-
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
-
Rouits E, Charasson V, Petain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E, Robert J, Gamelin E (2008) Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer 99: 1239-1245
-
(2008)
Br J Cancer
, vol.99
, pp. 1239-1245
-
-
Rouits, E.1
Charasson, V.2
Petain, A.3
Boisdron-Celle, M.4
Delord, J.P.5
Fonck, M.6
Laurand, A.7
Poirier, A.L.8
Morel, A.9
Chatelut, E.10
Robert, J.11
Gamelin, E.12
-
31
-
-
36048992408
-
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
-
DOI 10.1200/JCO.2007.12.8637
-
Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ (2007) Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25: 4793-4799 (Pubitemid 350086483)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.30
, pp. 4793-4799
-
-
Saltz, L.B.1
Rosen, L.S.2
Marshall, J.L.3
Belt, R.J.4
Hurwitz, H.I.5
Eckhardt, S.G.6
Bergsland, E.K.7
Haller, D.G.8
Lockhart, A.C.9
Rocha Lima, C.M.10
Huang, X.11
DePrimo, S.E.12
Chow-Maneval, E.13
Chao, R.C.14
Lenz, H.J.15
-
32
-
-
39149120621
-
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
-
DOI 10.1200/JCO.2007.13.9303
-
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650-656 (Pubitemid 351264362)
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.4
, pp. 650-656
-
-
Socinski, M.A.1
Novello, S.2
Brahmer, J.R.3
Rosell, R.4
Sanchez, J.M.5
Belani, C.P.6
Govindan, R.7
Atkins, J.N.8
Gillenwater, H.H.9
Pallares, C.10
Tye, L.11
Selaru, P.12
Chao, R.C.13
Scagliotti, G.V.14
-
33
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
|